Sentynl Therapeutics, Inc.
Michael Hercz serves as the Senior Vice President, General Counsel & Chief Compliance Officer at Sentynl Therapeutics, Inc. since September 2015, overseeing legal, compliance, regulatory, human resources, risk management, and corporate communications functions. Previously, Michael held the position of Managing Director at Deloitte within the Governance, Regulatory and Risk Strategies practice, assisting Fortune 500 clients in the life sciences and healthcare sectors. Prior roles include Vice President, Law & Chief Compliance Officer at Victory Pharma, and various positions at Amgen Inc., culminating as Executive Director of Enterprise Risk Management. Michael began legal career as an associate at Akin, Gump, Strauss, Hauer & Feld and Hooper, Lundy & Bookman, PC. Educational background includes a Juris Doctor degree from USC Gould School of Law and a Bachelor of Arts in Psychology from the University of Pennsylvania.
Sentynl Therapeutics, Inc.
Sentynl Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Ltd., is a commercial stage biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases.